The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Geeman Happy NY. Wishing this year would be a prosperous one for u. I've also been following AGL for some time. Bought when they got FDA clearance and then sold at a loss soon after when I realised it lost momentum. That was when it was 150p... now it's crazy 27p.. but market cap it around 70mil with 30mil cash in bank so could go down more. No idea where the bottom is... Any thoughts? I am done catching bottoms like I did with Eve sleep.. adjusting my strategy to trying to buy on the way up. Lets see how that works. ONC is also in liquid biopsies too.. except their US distributor is starting to show some legs and a bit of results.
Great to have u on board Wyn. Good you have a bit of skin in the game. Look forward to ur future analysis and opinions :)
Thanks for your valuable TA and opinions as always!
Yes certainly very interesting company, the FA is very attractive especially their exclusive US distributor Biodesix has just raised $90m to further support the commercialisation efforts of their main product from Oncimmune. Their liquid biopsy for diagnosing lung cancer has medicare coverage and yesterday announced the signings with 4 private payer insurance coverage too. Hopefully results in higher sales and royalty payments to ONC.
Hi guys, would be great to learn your opinions on the following company Oncimmune (ONC), also similar to Angle a liquid biopsy company but ONC also provides big pharma with CRO related biomarker services. Would be good to learn ur comments. Also from Wyn from a TA perspective. Thanks.
Onwards and upwards
More good news, Oncimmune's US distributor signs 4 new four private payers insurance coverage of approximately 4.5 million people.
Biodesix Announces First Four Private Payer Coverage Policies for the Nodify XL2® Test - link below
https://investors.biodesix.com/news-releases/news-release-details/biodesix-announces-first-four-private-payer-coverage-policies
Certain directors intending to subscribe for £1.2mln- I am guessing a large proportion of that is from the new Chairman Alistair. I guessing the new appointed non-exe director John Goold who just started a new fund listed on LSE will also invest. This looks like insiders taking a position before the company reaches inflexion point next year with EarlyCDT Lung expected to grow significantly over the short-term as Biodesix their US distributor raises $90mil to fund expansion. I have high hopes for this one 12 months from now. GLA, DYOR, IMO.
Good question Gamblors, I did not find the royalty numbers. But it does say Biodesix will pay Oncimmune a total of $28 million over five years. I am guessing this is equivalent to the licensing rights for EarlyCDT excluding COGS and Royalty.
https://www.fiercebiotech.com/medtech/biodesix-acquires-oncimmune-s-u-s-lab-for-rule-lung-nodule-cancer-blood-test
Biodesix which is Oncimmune's USA distributor of EarlyCDT Lung raised $40m equity + $50m debt totalling $90m to drive commercial sales of their core lung-diagnostic business which mainly consists of Oncimmune's EarlyCDT Lung rights. This hopefully will drive sales and bring more royalty payments to Oncimmune.
I am hoping Adam Hill and his team can deliver some positive news to drive up the share price so we can raise some capital to further invest in the business. IMO , DYOR
It would be very meaningful if Chairman decides to have skin in the game. He's LOADED. At current market cap, he could probably afford to buy out the company by himself, not saying he would but just to mention his compensation at Syneos as CEO was around £6-8mil per year. A serious several £million investment in ONC would definitely align interests and bring excitement for all shareholders. I hope he is not passive in taking this company to the next growth stages. A small company like Oncimmune requires his help to wisdom, expertise and most importantly action.
They are not desperate to raise funds currently but I guess if the right investor (s) comes along with interest, then it's always good to have more money to invest in growth, hopefully can raise capital at a premium rather than a discount like previously. IMO, DYOR
Good news, it's now the 3rd deal in 5 years. It does demonstrate they have the tech and ability to make good deals. But like previous deals, there has been a pattern, after every deal so far has been followed by a fund raise. The issue with this business model is it relies heavily on upfront payment (2m for this deal)+ milestone payments and then royalty on sales which will takes a long time/many years. Therefore C4x will need to keep raising funds to maintain operations and invest until they have many potential assets in the pipeline. IMO, DYOR.
Are retail investors going to get wiped out? Follows a similar pattern to the most recent rights issue. Appalling.
Looks like Jim has lost interest in continuously funding this project when we are facing long timelines to production. The reality is, it is very difficult, timely and costly to get gold in scale from these mines. Cut loses and move on. If he is confident in a big return, he won't sell now after all these years of investment.. IMO, DYOR.
New CEO, looks like a good appointment. Opening markets positive
Mr Diamond is going to have to pick up the phone to Qatar friend's for more oil money if he wants this deal done. I think he needs at least 40p+ (£60mil) to convince the board. IMO, DYOR.
Meagre deal indeed, I am doubtful Sam Smith would agree considering she bought 350k shares at 31p in Feb 2022 and also it is her "Baby"; so I think anything south of 30p is pretty lame offer IMO, DYOR.
20p a share... only 10% more than current levels. Not so attractive for shareholders.
https://news.sky.com/story/diamonds-panmure-in-talks-about-37m-takeover-of-finncap-12748897
An interesting company BUT the prior results tell the story reflected in the share price. Not much cash in the bank and a lot of debt. IMO, if don't get a fund raise soon, they are heading to big trouble. Not easy to raise capital in these economic environments. Hope they are able to raise without a significant discount. IMO, DYOR.
-Revenue £3.86M
-Loss £9.90M
-Share-based payments £1.80M
-Cash £2.53M
-net debt £8.16M